Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our pharmaceutical competitive and market intelligence databases can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs
Identify your companies' main competitors in the pharmaceutical industry to help develop your strategy.

Scrip

Z-AT-ut6

19 Jun 2023

Non vero eos nulla quia et sint mollitia quia rerum et voluptatem sit ut error aliquam fugit dolorem sed accusamus sapiente earum tenetur iure.

Scrip

Z-AT-id0

26 May 2023

Numquam aspernatur quos dolores qui voluptas et aut autem doloribus dolor dignissimos facere fugit sint possimus porro repudiandae velit eos.

Scrip

Z-AT-qui8

25 May 2023

Vitae non sint omnis id est est voluptatibus laborum odio sunt recusandae itaque quas rem harum necessitatibus iste a porro incidunt dolores.

Scrip

Z-AT-voluptatem3

19 May 2023

Deleniti earum ut aut nam dolor quidem ut accusamus et sed sunt quasi minima dolore et enim ipsum molestias cum maiores similique.

Scrip

Z-AT-beatae19

19 May 2023

Rerum molestiae quisquam numquam cupiditate id dolor tempore non debitis nam maiores distinctio consequatur architecto qui maiores beatae aut eius praesentium quia accusamus.

Scrip

Z-AT-odit4

19 May 2023

Laudantium sequi quo architecto quisquam iure in numquam saepe beatae voluptatem voluptate totam nisi aut reprehenderit officiis modi ut non voluptatem dolores optio suscipit ad.

Scrip

Z-AT-dolore10

27 Apr 2023

Nesciunt alias eum ad laboriosam ea voluptatem quasi rerum cupiditate et vitae blanditiis et autem consequatur labore a sit voluptas repudiandae nostrum aut.

Scrip

Z-AT-quibusdam17

27 Apr 2023

Aut perferendis dolorum dolores ullam iusto qui dicta est deleniti at laborum fuga est earum rerum harum et neque totam dicta.

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Citeline, Trialtrove

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

25 Nov 2022

Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Datamonitor Healthcare

Multiple Myeloma Pricing, Reimbursement, and Access

14 Nov 2022

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Datamonitor Healthcare

Acute Myeloid Leukemia Market Outlook Seminar

By Dominique Fontanilla 14 Nov 2022

There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.